Paduch McKenzie, Thomason Angela R
Samford University McWhorter School of Pharmacy, Birmingham, AL, USA.
Hosp Pharm. 2022 Feb;57(1):188-192. doi: 10.1177/0018578720985438. Epub 2021 Jan 9.
The increase use of cannabidiol containing products poses potential risks with high-alert medications such as oral anticoagulants. To review the use of cannabidiol and its' derivatives with oral anticoagulants, searches (2005-May 2020) were performed by PubMed, Google Scholar, and ClinicalTrials.gov. Articles were limited to English-language only. The results yielded 4 case reports evaluating the potential drug interactions between cannabinoids and its' derivatives and oral anticoagulants. These case reports show the potential for drug interactions when using warfarin and cannabidiol containing products. At time of publication, there were no published articles on drug interactions between cannabidiol and the direct oral anticoagulants. Further research is needed to conclude drug interactions are associated with an increased risk of bleeding or thromboembolic events in these patients.
含大麻二酚产品使用的增加，给口服抗凝剂等高警示药物带来了潜在风险。为了回顾大麻二酚及其衍生物与口服抗凝剂的联合使用情况，我们通过PubMed、谷歌学术和ClinicalTrials.gov进行了检索（2005年至2020年5月）。纳入的文章仅限于英文。检索结果产生了4篇病例报告，评估了大麻素及其衍生物与口服抗凝剂之间潜在的药物相互作用。这些病例报告显示，在使用华法林和含大麻二酚产品时存在药物相互作用的可能性。在发表时，尚无关于大麻二酚与直接口服抗凝剂之间药物相互作用的已发表文章。需要进一步研究以确定这些患者中药物相互作用是否与出血或血栓栓塞事件风险增加相关。
